Skip to content
Disclosery

AJU IB Investment Co., Ltd.

Follow

13F filer, CIK 1710065, Seoul, Korea Republic of

AJU IB Investment Co., Ltd. reported $115,120,361 across 7 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-06.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001140361-25-040613

Period
2025-09-30
Reported value
$115M
Holdings
7
Top 10 weight
100%
New
0
Sold out
1

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CARMexited-718,332-$281K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001140361-25-040613, largest first. % of portfolio is the value over $115,120,361, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 1,047,557 shares; 2025Q1: 1,047,557 shares; 2025Q2: 1,047,557 shares; 2025Q3: 1,047,557 shares 1,047,557$86M74.71%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 457,059 shares; 2025Q1: 457,059 shares; 2025Q2: 457,059 shares; 2025Q3: 457,059 shares 457,059$25.9M22.47%0Timeline
SEERSEER INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 816,375 shares; 2025Q1: 816,375 shares; 2025Q2: 816,375 shares; 2025Q3: 816,375 shares 816,375$1.8M1.57%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 667,742 shares; 2025Q1: 667,742 shares; 2025Q2: 667,742 shares; 2025Q3: 667,742 shares 667,742$596K0.52%0Timeline
RALLYBIO CORPRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 754,678 shares; 2025Q1: 754,678 shares; 2025Q2: 754,678 shares; 2025Q3: 754,678 shares 754,678$377K0.33%0
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 99,503 shares; 2025Q1: 99,503 shares; 2025Q2: 12,437 shares; 2025Q3: 12,437 shares 12,437$321K0.28%0
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 175,000 shares; 2025Q1: 175,000 shares; 2025Q2: 175,000 shares; 2025Q3: 175,000 shares 175,000$153K0.13%0

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CARMCARISMA THERAPEUTICS INC COM718,332$281Kshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001140361-25-040613 base2025-11-06acceptance time not in the bulk data set